Genetic Technologies Ltd (GENE)
NASDAQ (CM) NASDAQ (CM) Primary 
FDA Accepts BridgeBio's Filing for Rare Genetic Disease Drug
BBIO's FDA filing for encaleret in ADH1 has been accepted, moving the rare disease candidate closer to a decision expected by May 2027.
Soleno Therapeutics Secures FDA Approval For Its First Commercial Drug For Rare Genetic Disorder
The U.S. Food and Drug Administration (FDA) on Wednesday approved Soleno Therapeutics, Inc.'s SLNO Vykat XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, for hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome (PWS).
23andMe's Bankruptcy Sparks Privacy Concerns Over Genetic Database Of 15 Million Customers
On Sunday, human genetics and biotechnology company 23andMe Holding Co ME voluntarily filed for Chapter 11 bankruptcy to enable a sale process to maximize its business value.
Genetic testing firm 23andMe files for bankruptcy
US genetic testing company 23andMe has filed for bankruptcy and is looking for a buyer, after rejecting a takeover offer from its resigning CEO.
23andMe Is Bankrupt. Here's What You Need to Know About Your Genetic Data
The genetic testing company, which plans to try to sell all of its assets, holds biological information on millions of people.
Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via Equity
On Monday, Beam Therapeutics Inc. BEAM announced initial safety and efficacy data from its Phase 1/2 trial of BEAM-302, establishing clinical proof-of-concept as a potential treatment for alpha-1 antitrypsin deficiency (AATD) and for in vivo base editing.
Rhythm Pharmaceuticals: Buying This Rare Genetic Obesity Maven
Rhythm Pharmaceuticals' 01/2025 presentation and Q4 2024 preliminary results press release highlight growing financial performance and promising pipeline developments. Investment thesis focuses on Rhythm's robust clinical progress and strategic positioning in the rare genetic obesity market. Rating justification is based on solid revenues, innovative product pipeline, and potential market expansion.
Telomir Pharmaceuticals Confirms Lifespan Restoration and Normalization of Accelerated Aging in Preclinical Model of Progeria (A Rare Genetic Disorder Causing Rapid Aging)
MIAMI, FL / ACCESSWIRE / January 7, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir"), an emerging leader in age-reversal science focused on treating the root causes of diseases rather than just their symptoms, announced today potentially groundbreaking findings from a preclinical progeria lifespan study conducted in collaboration with Nagi Bioscience SA. Utilizing C.
FDA Approves Ionis Pharmaceuticals' Rare Genetic Disease Therapy to Lower High-Level Of Fat In Blood
On Thursday, the FDA approved Ionis Pharmaceuticals, Inc.'s IONS Tryngolza (olezarsen) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), a rare, genetic form of severe hypertriglyceridemia (SHTG) that can lead to acute pancreatitis (AP).
Neurocrine Wins FDA Approval For Genetic Disorder Drug
Neurocrine Biosciences won Food and Drug Administration approval late Friday for the first new treatment for an adrenal disease in decades. The post Neurocrine Wins FDA Approval For Genetic Disorder Drug appeared first on Investor's Business Daily.
Penny Stock Spruce Biosciences Winds Down Tildacerfont Studies For Rare Genetic Disorder
On Tuesday, Spruce Biosciences, Inc. SPRB revealed topline results from its CAHmelia-204 study of tildacerfont in adult CAH and its CAHptain-205 study of tildacerfont in adult and pediatric CAH.
Genetic Testing Firm GeneDx Reports Narrower Q3 Loss As Revenues Surge, Lifts Annual Guidance
GeneDx Holdings WGS stock is trading higher on Tuesday.
